Alphatec Holdings, Inc. (ATEC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Alphatec Holdings, Inc. (ATEC) Healthcare & Pipeline Overview

Alphatec Holdings, Inc. (ATEC) is a medical technology company specializing in innovative solutions for spinal disorders, including advanced surgical systems and biologics. ATEC's focus on neural safety and minimally invasive techniques positions it within the competitive medical device landscape, serving a growing market for spinal treatments.

What Is the Investment Thesis for ATEC?

With a market capitalization of $1.36B, ATEC is positioned to capitalize on the increasing demand for advanced spinal treatments. The company's SafeOp Neural InformatiX System and Sigma series of access systems offer unique value propositions by reducing nerve injury risks and improving surgical precision. Key growth catalysts include the continued adoption of ATEC's minimally invasive surgical solutions and the expansion of its biologics offerings. The company's gross margin of 65.3% indicates strong pricing power and efficient operations. However, the negative profit margin of -15.9% highlights the need for improved cost management and increased sales volume to achieve profitability. The company's beta of 1.04 suggests a market correlation. Investors should monitor ATEC's ability to drive revenue growth, manage expenses, and navigate the competitive landscape to realize its full potential.

Based on FMP financials and quantitative analysis

ATEC Key Highlights

Market capitalization of $1.36B, reflecting investor confidence in Alphatec's growth potential.

• Gross margin of 65.3%, indicating strong pricing power and efficient cost management in product sales.
• Offers SafeOp Neural InformatiX System, a key differentiator designed to reduce the risk of intraoperative nerve injury.
• Comprehensive product portfolio includes spinal fixation systems, interbody implants, and biologics, addressing a wide range of spinal disorders.
• Distribution network through independent distributors and direct sales representatives in the United States, ensuring broad market access.

Who Are ATEC's Competitors?

ATEC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ATEC's Key Strengths?

Innovative product portfolio with proprietary technologies like SafeOp.

• Comprehensive range of spinal fixation systems, interbody implants, and biologics.
• Established distribution network in the United States.
• Strong focus on research and development.

What Are ATEC's Weaknesses?

Negative profit margin (-15.9%) indicating profitability challenges.

• Reliance on independent distributors for sales and marketing.
• Limited geographic presence outside the United States.
• High competition in the medical device industry.

What Could Drive ATEC Stock Higher?

ATEC catalyst: Launch of new spinal fixation systems and interbody implants in Q3 2026, expanding the product portfolio.

• Continued adoption of the SafeOp Neural InformatiX System, driving revenue growth and market share.
• Expansion of biologics offerings through research and development, enhancing surgical outcomes.

What Are the Key Risks for ATEC?

Financial-distress signal — its Altman Z-Score of -0.53 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Product liability lawsuits related to spinal surgery devices, impacting financial performance and reputation.
• Regulatory changes affecting the approval and marketing of medical devices, increasing compliance costs.
• Intense competition from established medical device companies, limiting market share and pricing power.

What Are the Growth Opportunities for ATEC?

• Expansion of Minimally Invasive Surgery (MIS) Solutions: The market for minimally invasive spinal surgery is growing due to reduced recovery times and improved patient outcomes. Alphatec's Invictus MIS SingleStep System and squadron lateral retractor are well-positioned to capitalize on this trend. By investing in R&D and surgeon training programs, Alphatec can increase adoption of its MIS solutions, targeting a market estimated to reach $3.5 billion by 2028.
• Strategic Partnerships and Acquisitions: Forming strategic alliances with hospitals, research institutions, and other medical device companies can accelerate product development and market penetration. Acquiring complementary technologies or companies can expand Alphatec's product portfolio and geographic reach. This approach can drive revenue growth and enhance the company's competitive position, potentially adding $50-100 million in revenue within the next 3-5 years.
• Geographic Expansion: While Alphatec primarily operates in the United States, expanding into international markets, particularly Europe and Asia, represents a significant growth opportunity. These regions have a growing demand for advanced spinal surgery solutions. Establishing distribution networks and obtaining regulatory approvals in key international markets can unlock new revenue streams and diversify the company's customer base, potentially contributing 15-20% to overall revenue growth over the next 5 years.
• Development of Advanced Biologics: The market for spinal biologics, including bone grafts and regenerative materials, is expanding due to their ability to promote bone fusion and improve surgical outcomes. Alphatec's biologics offerings, such as Alphagraft Demineralized and Cellular Bone Matrix, can be further enhanced through research and development of novel regenerative technologies. Capturing a larger share of the biologics market, estimated at $2.8 billion, can significantly boost Alphatec's revenue and profitability.
• Integration of Artificial Intelligence (AI) and Data Analytics: Incorporating AI and data analytics into spinal surgery planning and execution can improve surgical precision and patient outcomes. Alphatec can leverage its Alpha InformatiX product platform to develop AI-powered tools that assist surgeons in preoperative planning, intraoperative navigation, and postoperative monitoring. This technological advancement can differentiate Alphatec from competitors and attract surgeons seeking cutting-edge solutions, potentially increasing market share by 10-15% within the next 3-5 years.

What Threats Does ATEC Face?

• Intense competition from established medical device companies.
• Regulatory hurdles and compliance requirements.
• Product liability risks associated with spinal surgery devices.
• Economic downturns affecting hospital budgets and capital expenditures.

What Are ATEC's Competitive Advantages?

• Proprietary Technologies: Alphatec's SafeOp Neural InformatiX System provides a unique advantage by reducing the risk of nerve injury during spinal surgery.
• Comprehensive Product Portfolio: The company offers a wide range of spinal fixation systems, interbody implants, and biologics, providing a comprehensive solution for spinal disorders.
• Strong Distribution Network: Alphatec's network of independent distributors and direct sales representatives ensures broad market access and customer support.
• Innovation and R&D: Continuous investment in research and development allows Alphatec to develop innovative products and maintain a competitive edge.

What Does ATEC Do?

Founded in 1990 and headquartered in Carlsbad, California, Alphatec Holdings, Inc. has evolved into a prominent medical technology company focused on designing, developing, and advancing technologies for the surgical treatment of spinal disorders. The company's comprehensive portfolio includes a range of products, such as the SafeOp Neural InformatiX System, designed to mitigate the risk of intraoperative nerve injury, and the Sigma transforaminal lumbar interbody fusion pedicle-based access system, which enhances visualization of anatomical landmarks during surgery. Alphatec also offers the Invictus Spinal Fixation System, a thoracolumbar fixation system used to treat various spinal pathologies, and the Arsenal spinal fixation system, a comprehensive platform for addressing degenerative and deformity-related spinal conditions. Alphatec's product line extends to interbody implants like IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants, as well as biologics, including Cervical Structural Allograft Spacers and Alphagraft Demineralized and Cellular Bone Matrix. The company's commitment to innovation is evident in its development of minimally invasive surgical solutions and advanced imaging technologies, such as EOS imaging products. Alphatec distributes its products through a network of independent distributors and direct sales representatives across the United States, ensuring broad market access and customer support. Alphatec aims to deliver clinical value and improve patient outcomes through its comprehensive suite of spinal surgery solutions.

What Products and Services Does ATEC Offer?

• Designs and develops technologies for surgical treatment of spinal disorders.
• Offers the SafeOp Neural InformatiX System to reduce intraoperative nerve injury risks.
• Provides Sigma transforaminal lumbar interbody fusion pedicle-based access system for enhanced surgical visualization.
• Manufactures the Invictus Spinal Fixation System for treating a range of spinal pathologies.
• Offers a range of interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants.
• Provides biologics such as Cervical Structural Allograft Spacers and Alphagraft Demineralized and Cellular Bone Matrix.
• Sells EOS imaging products for advanced spinal imaging.

How Does ATEC Make Money?

• Designs, develops, and manufactures spinal surgery technologies and products.
• Sells products through a network of independent distributors and direct sales representatives.
• Generates revenue from the sale of spinal fixation systems, interbody implants, and biologics.
• Invests in research and development to innovate and expand its product portfolio.

What Industry Does ATEC Operate In?

Alphatec Holdings, Inc. operates within the medical device industry, specifically focusing on spinal surgery solutions. The global spinal device market is characterized by technological advancements, increasing demand for minimally invasive procedures, and an aging population. Key trends include the adoption of robotic surgery, personalized implants, and advanced biologics. Alphatec competes with established players by offering innovative products like the SafeOp system and a comprehensive range of spinal fixation and interbody solutions. The company's focus on neural safety and surgical precision positions it to capture market share in this competitive landscape.

Who Are ATEC's Key Customers?

• Spinal surgeons who perform surgical procedures to treat spinal disorders.
• Hospitals and surgical centers that utilize spinal surgery technologies and products.
• Patients who require surgical treatment for spinal conditions.
• Independent distributors who sell and market Alphatec's products to healthcare providers.

Alphatec Holdings, Inc. Financial Trajectory

Alphatec Holdings, Inc. (ATEC) reported $213.5M in revenue for Jun 2026, reflecting 11.1% growth compared to the prior quarter. The company recorded a net loss of $25.8M, with diluted EPS of $-0.17. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ATEC averaged $-0.18 in diluted EPS.

Company Profile

Alphatec Holdings, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO Patrick S. Miles. ATEC has traded publicly since 2006.

How Alphatec Holdings, Inc. Is Valued

Alphatec Holdings, Inc. carries a market capitalization of $1.36B, placing it in the small-cap category. Analyst price targets span from $12.00 to $24.00, with a consensus of $16.22. At the current price of $8.84, that implies approximately 83% upside potential. Relative to its peer group, ATEC's quantitative score of 18/100 is below the peer average of 45/100.

Return on assets is -15.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.90 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.0%, the inverse of the P/E and a quick read on earnings relative to price.

Alphatec Holdings, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.53 places it in the distress zone, a signal of elevated financial risk.

Alphatec Holdings, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 230.1% below estimates on average.

Wall Street analysts project Alphatec Holdings, Inc. revenue of about $882.1M for fiscal 2026, with EPS near $0.33. The estimate reflects 10 contributing analysts.

Over the past six months, Alphatec Holdings, Inc. insiders filed 21 SEC Form 4 transactions — 7 sales and 14 purchases. On net that is roughly 404K shares acquired (about $1.6M) — insiders putting money in tends to read as conviction.

ATEC Financials

ATEC Latest News

ATEC Analyst Consensus

ATEC MoonshotScore

Alphatec Holdings, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources